Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
.png?la=en-us)
Join us for the 10th anniversary of the Global Generics and Biosimilars Awards celebrating the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals.
Co-locating with CPhI Worldwide in Barcelona, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and new for 2023, Campaign of the Year.
The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is Monday, 4 September, 2023, and the qualifying period for submissions is 1 August 2022 - 31 August 2023. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 25 October 2023.
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
Evidence cited in supporting text could include: details of the expected benefits of the acquisition, including anticipated synergies and integration goals as well as strategic or cultural fit. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
Evidence cited in supporting text could include: evidence of successful strategies or initiatives implemented, executive team management, industry-level leadership or positive effects on company culture. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
Evidence cited in supporting text could include: innovation, addressing unmet needs, overcoming regulatory or technology obstacles, intellectual property triumphs or marketing success. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
Evidence cited in supporting text could include: details of the expected benefits of the business development activities, including anticipated financial or strategic advantages. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.
Evidence cited in supporting text could include: details of manufacturing excellence, supply security, customer service, technological achievements or increased efficiencies. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
Evidence cited in supporting text could include: strategic advantages, details of overcoming development or technology obstacles, manufacturing efficiency or intellectual property triumphs. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.
Evidence cited in supporting text could include: industry thought leadership, outreach achieved, social media and media interest or collaboration with regulatory authorities. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
Evidence cited in supporting text could include: details of overcoming development or technology obstacles, competitive advantages, regulatory efficiency or benefits to patient populations. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
Evidence cited in supporting text could include: details of the positive impact of CSR activities, innovative or original approaches to CSR, or positive corporate cultural changes. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.
Evidence cited in supporting text could include: details of outstanding collaborations with generics, biosimilars or value-added medicines suppliers, customer service, or innovations benefiting the off-patent industry. The activities in question should have taken place between 1 August 2022 – 31 August 2023.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Aurelio Arias
Stuart Colligon
Duncan Emerton
Vivian Frittelli
Chloe Kent
Jim Keon
Suzette Kox
Ewan Livesey
Axel Muller
Marnie Peterson
Julie Reed
Dean Rudge
Alan Sheppard
Adrian Van Der Hoven
Warwick Smith
James Vane Tempest
David Wallace
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis.
Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.
Prior to IQVIA, Aurelio has worked in R&D and in various strategy consulting roles. He holds an MSci in Chemistry from Imperial College London.
Stuart founded Panacea in 2008 after several years of working in the generics arm of the Pharma industry. Panacea provides pharmacovigilance, regulatory affairs and quality assurance services to the industry globally. He has gained experience in board positions of a range of companies over a 30 year career, with particular focus on strategic direction, change management, business development and corporate communication.
Jim Keon is President of the Canadian Generic Pharmaceutical Association (CGPA), and President of Biosimilars Canada organizations representing Canada’s generic and biosimilar pharmaceutical sectors.
Jim graduated with an M.A. in Economics from Queen’s University and has more than 25 years experience in the pharmaceutical sector.
Jim has served as President of the CGPA since 1998 and was named the founding President of Biosimilars Canada in January 2015. Prior to joining CGPA in 1994 he held senior positions in the federal government and was directly involved in international trade negotiations for NAFTA and the WTO, as well as Canada’s inter-provincial trade negotiations.
Jim is a past Chair and a current member of the Management Committee of the International Generic and Biosimilars Medicines Association (IGBA). The IGBA is committed to promoting the interests of generic and biosimilars medicines around the world.
Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020).
Ewan currently works as a consultant to several companies and PE firms advising on corporate strategy including all elements of business development from acquisition to licensing and portfolio selection.
Co-founder and CEO of nucleo (www.go-nucleo.com)
Axel Müller - by education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013.
Since 2014 Axel is working as Consultant – mainly but not only in the Pharmaceutical Industry. After some years working as Senior Advisor of Arthur D. Little he joined 2018 Fidelio Healthcare Partners as Associated Partner. In addition, Axel is non-executive member of several supervisory and advisory boards.
Marnie Peterson is Chief Executive Officer of the Australian Generic and Biosimilar Medicines Association (GBMA) and previously lead the organisation’s educational arm, GBMA Education, responsible for a 4-year educational grant focussed on biosimilar medicines.
With over 17 years in leadership, business management and marketing, Marnie’s pharmaceutical experience spans key executive roles in large generic pharma, company start-ups and business ownership.
The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
Juliana (Julie) Reed currently serves as the Executive Director of the Biosimilars Forum, leading strategy for the group’s strategic efforts to increase access to and adoption of biosimilars. Reed served as the Forum’s President for more than eight years and was one of its founders. As the Biosimilars Forum President, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States. She brings more than 30 years of experience in the healthcare sector to the Forum. Most recently, Reed was Vice President and Global Corporate Affairs Lead with Pfizer, specializing in immunology, inflammation and biosimilars portfolios. She also has experience in executive roles leading global corporate and government affairs for Hospira and Coherus BioSciences.
Alan Sheppard, managing director, Ascher Resources with 50 years extensive global healthcare experience, including innovator R&D pharmaceuticals, OTC and generic companies, working with government departments, law firms, venture capital companies and industry associations. Alan was Principal, Thought Leadership Global Generics and Biosimilars, IMS Health; Exec VP, Europe Generics Dr Reddy’s; VP, Global Corporate Strategy PLIVA; European Marketing Director, Medeva. Earlier positions: General Manager, Rhône-Poulenc Rorer UK; Marketing Director, Revlon Healthcare; General Manager, Institute Mérieux UK; management roles with Servier, SmithKline & French and Upjohn. Alan has been an expert witness, patent litigation; a guest lecturer, University of Wales; Chairman, Technical Advisory Group, Access to Medicines Foundation; member, PMCPA Appeals Board and Fellow, International Doctors’ Association.
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Warwick Smith was Director and then Director General of the British Generic Manufacturers Association (BGMA) for 25 years until December 2020. During that time, he was responsible for the launch of the British Biosimilars Association (BBA) and the negotiation with the British Department of Health of the generic medicines pricing and supply agreements which gave the suppliers of unbranded medicines freedom of pricing in the UK. For much of that period, he was a member of the Board and Executive of Medicines for Europe. Prior to that, he worked for the UK Government as a policy adviser, international negotiator and ministerial aide, before leaving to become a public affairs adviser in which capacity he helped launch the BGMA with UK Government support.
Ready to submit your entry to the Global Generics & Biosimilars Awards 2023? Enter today to be in with a chance of winning
Enter Now
Sponsorship of the 10th Anniversary Global Generics & Biosimilars awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.
Sponsor Opportunities
Looking to attend the 10th Anniversary Global Generics and Biosimilars Awards 2023? Book your place today!
Book your place
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets.
Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion to making a difference for partners and improve the lives of patients around the world.
Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
Pharmawise is a leading boutique consulting firm focused on generic and biosimilar market expertise. Since 2006, we have conducted 150+ projects for leading financial institutions, generic and pharmaceutical companies, spanning:
We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.
If your responsibilities match our expertise, we would love to hear from you. Contact us at www.pharma-wise.com
The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
